The EMJ Podcast | Episode 162
This week, Jonathan is joined by Sophie Lanzkron, Professor of Medicine in the Division of Hematology at the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The pair explores sickle cell disease and advancements in its treatment, including hydroxyurea and blood transfusions, as well as advancements in haplotype transplant and gene therapy. They further discuss challenges in diagnosis and treatment, and how the condition affects quality of life.
Spotify | Apple | Amazon Music | Download MP3 (33:42 mins)
Speaker bio:
Sophie Lanzkron completed her BA in Biology at Brandeis University in Waltham, Massachusetts, USA. She continued her education at the Albert Einstein College of Medicine in New York City, USA, graduating in 1991 as a Doctor of Medicine. Her training then took her to Baltimore, Maryland, USA, where she stayed, first as a Resident of Internal Medicine at the University Maryland Medical System, and then as a Fellow in Hematology at the Johns Hopkins School of Medicine. She is now Professor of Medicine in the Division of Hematology at the Johns Hopkins University School of Medicine.
Lanzkron also sits on a number of medical boards and committees, and has been Chair of the Patient Engagement Committee for the American Society of Hematology’s sickle cell clinical trials network for the past 3 years. Her research focus is on sickle cell disease, where she is looking for innovative approaches to improving quality of care for adults with sickle cell disease.
